Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.61409/V12230800 | DOI Listing |
Publication Analysis
Top Keywords
severe rsv
8
rsv infection
8
[not available]
4
available] respiratory
4
respiratory syncytial
4
syncytial virus
4
virus rsv
4
rsv common
4
common respiratory
4
respiratory virus
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!